RT Journal Article
SR Electronic
T1 Low Gut Ruminococcaceae Levels are Associated with Occurrence of Antibiotic-associated Diarrhea
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.23.21263551
DO 10.1101/2021.09.23.21263551
A1 Gu, Xiaoqiong
A1 Sim, Jean XY
A1 Lee, Wei Lin
A1 Cui, Liang
A1 Chan, Yvonne FZ
A1 Chang, Ega Danu
A1 Teh, Yii Ean
A1 Zhang, An-Ni
A1 Armas, Federica
A1 Chandra, Franciscus
A1 Chen, Hongjie
A1 Zhao, Shijie
A1 Lee, Zhanyi
A1 Thompson, Janelle R.
A1 Ooi, Eng Eong
A1 Low, Jenny G.
A1 Alm, Eric J.
A1 Kalimuddin, Shirin
YR 2021
UL http://medrxiv.org/content/early/2021/09/24/2021.09.23.21263551.abstract
AB Patients receiving antibiotics often suffer from antibiotic-associated diarrhea (AAD). AAD is of clinical significance as it can result in premature antibiotic discontinuation and suboptimal treatment of infection. The drivers of AAD however, remain poorly understood. We sought to understand if differences in the gut microbiome, both at baseline and during antibiotic administration, would influence the development of AAD. We administered a 3-day course of oral amoxicillin-clavulanate to 30 healthy adult volunteers, and performed a detailed interrogation of their stool microbiome at baseline and up to 4-weeks post antibiotic administration, using 16S rRNA gene sequencing. Lower levels of Ruminococcaceae were significantly and consistently observed from baseline till Day 7 in participants who developed AAD. The probability of AAD could be predicted based on qPCR-derived levels of Faecalibacterium prausnitzii, the most dominant species within the Ruminococcaceae family. Overall, participants who developed AAD experienced a greater decrease in microbial diversity during antibiotic dosing. Our findings suggest that a lack of gut Ruminococcaceae at baseline influences development of AAD. In addition, quantification of F. prausnitzii in stool prior to antibiotic administration may help identify patients at risk of AAD, and aid clinicians in devising individualised treatment regimens to minimise such adverse effects.Competing Interest StatementE.J.A is a co-founder and shareholder of Finch Therapeutics, a company that specializes in microbiome-targeted therapeutics. All the other authors have declared that no conflict of interest exists.Clinical TrialNCT04156555Funding StatementThis study was funded by a SingHealth Academic Medicine Research Grant (AM-CT003-2018) and the National Research Foundation, Singapore, under its Campus for Research Excellence and Technological Enterprise (CREATE) program funding to the Singapore-MIT Alliance for Research and Technology (SMART) Antimicrobial Resistance Interdisciplinary Research Group (AMR IRG).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the SingHealth Centralised Institutional Review Board (Ref: 2019/2377).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe sequencing datasets generated during this study are available at European Nucleotide Archive (ENA): PRJEB46061. Deposited data includes FASTQ files for the 197 16S rRNA amplicon sequences, with adaptors removed and filtered for good quality. The code to reproduce all of the analysis and figures in this paper is available at https://github.com/XiaoqiongGu/augmentin_16S/Final_Figure.